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AbstrACt
background Checkpoint inhibitors can induce profound 
anticancer responses, but programmed cell death 
protein-1 (PD-1) inhibition monotherapy has shown 
minimal activity in prostate cancer. A published report 
showed that men with prostate cancer who were resistant 
to the second- generation androgen receptor inhibitor 
enzalutamide had increased programmed death- ligand 
1 (PD- L1) expression on circulating antigen- presenting 
cells. We hypothesized that the addition of PD-1 inhibition 
in these patients could induce a meaningful cancer 
response.
Methods We evaluated enzalutamide plus the PD-1 
inhibitor pembrolizumab in a single- arm phase II 
study of 28 men with metastatic castration- resistant 
prostate cancer (mprogressing on enzalutamide alone. 
Pembrolizumab 200 mg intravenous was given every 
3 weeks for four doses with enzalutamide. The primary 
endpoint was prostate- specific antigen (PSA) decline of 
≥50%. Secondary endpoints were objective response, 
PSA progression- free survival (PFS), time to subsequent 
treatment, and time to death. Baseline tumor biopsies 
were obtained when feasible, and samples were 
sequenced and evaluated for the expression of PD- L1, 
microsatellite instability (MSI), mutational and neoepitope 
burdens.
results Five (18%) of 28 patients had a PSA decline 
of ≥50%. Three (25%) of 12 patients with measurable 
disease at baseline achieved an objective response. Of the 
five responders, two continue with PSA and radiographic 
response after 39.3 and 37.8 months. For the entire 
cohort, median follow- up was 37 months, and median PSA 
PFS time was 3.8 months (95% CI: 2.8 to 9.9 months). 
Time to subsequent treatment was 7.21 months (95% CI: 
5.1 to 11.1 months). Median overall survival for all 
patients was 21.9 months (95% CI: 14.7 to 28 .4 months), 
versus 41.7 months (95% CI: 22.16 to not reached (NR)) 
in the responders. Of the three responders with baseline 
biopsies, one had MSI high disease with mutations 
consistent with DNA- repair defects. None had detectable 
PD- L1 expression.
Conclusions Pembrolizumab has activity in mCRPC when 
added to enzalutamide. Responses were deep and durable 
and did not require tumor PD- L1 expression or DNA- repair 
defects.
trial registration number  clinicaltrials. gov 
(NCT02312557).
bACkground
Despite advancements in the management 
of metastatic castration- resistant prostate 
cancer (mCRPC), prostate cancer remains 
the second most common cause of cancer 
death in US men.1 Current therapies that 
extend survival for mCRPC include second- 
generation androgen receptor antagonists 
(enzalutamide), inhibitors of androgen 
synthesis (abiraterone), chemotherapy 
(docetaxel, cabazitaxel), a cellular vaccine 
(sipuleucel- T) and a radiopharmaceutical 
(radium-223).2–9 There are few data to guide 
sequencing of these agents and no data 
supporting routine use of combination ther-
apies. Management of mCRPC after enzalut-
amide and/or abiraterone is a particularly 
challenging clinical problem.
To date, immune checkpoint inhibitors 
used as monotherapy in mCRPC have shown 
mixed activity. Two phase III studies of the anti- 
Cytotoxic T Lymphocyte- Associated Protein-4 
(CTLA-4) antibody ipilimumab failed to meet 
their primary endpoint of improved overall 
survival, and early studies of programmed cell 
death protein-1 (PD-1) inhibitors showed no 
objective radiographic responses in men with 
mCRPC.10–12 Two recent studies examined 
single- agent pembrolizumab for programmed 
death ligand 1 (PD- L1) positive and PD- L1 
negative mCRPC. One enrolled only PD- L1 
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positive mCRPC (n=23), most of which had received 
prior docetaxel (91%), and a 17.4% durable response 
rate was observed.13 In the second study, all patients had 
received docetaxel, but there was no clear difference in 
response rate between those with PD- L1 positive (n=131) 
staining versus negative staining (n=67).14 Combinations 
of PD-1 inhibition with CTLA-4 and the poly- ADP ribose 
polymerase (PARP) inhibitor olaparib have also demon-
strated activity.15
Studies showed that PD- L1, a ligand for PD-1, was 
upregulated on dendritic cells in men with mCRPC either 
progressing on or refractory to enzalutamide.16 Primary 
prostate cancer tumors are considered ‘cold tumors’ 
poorly infiltrated with T cells, and there is a general lack 
of PD- L1 expression on prostate cancer cells.17 However, 
a recent analysis revealed that one- third of mCRPC biop-
sies exhibit PD-1 staining18 suggesting that strategies to 
enhance CD8+ T cell function and decrease inhibitory 
signals in the tumor may underlie the success of immu-
notherapies for prostate cancer. Since enzalutamide 
is associated with increased expression of PD- L116 and 
enzalutamide augments castration, we hypothesized that 
enzalutamide would be a strong partner to PD-1 inhib-
itors. Additionally, we previously reported a profound 
response to immunotherapy (anti- CTLA-4) in a man with 
mCRPC on enzalutamide with biochemical progression.19
Here we present the results of a phase II study exam-
ining the antitumor effect of pembrolizumab added 
to enzalutamide in men with mCRPC whose cancer is 
progressing on enzalutamide alone.
Methods
study design and conduct
All human investigations were carried out after approval 
by a local Human Investigations Committee and in accord 
with an assurance filed with and approved by the Depart-
ment of Health and Human Services. The data have been 
anonymized to protect the privacy of the participants. 
Investigators obtained informed consent from each 
participant.
The detailed clinical trial design has been described 
elsewhere.20 In brief, men with mCRPC progressing on 
enzalutamide by prostate- specific antigen (PSA) and/or 
imaging studies continued enzalutamide and received 
pembrolizumab 200 mg intravenously every 3 weeks for 
four doses. Subjects could have previously received sipu-
leucel- T and could have received abiraterone or chemo-
therapy for castration- sensitive disease, but previous 
treatment with PD-1, PD- L1 or CTLA-4 antibodies for any 
disease state was prohibited. Furthermore, subjects with 
a history of autoimmune disease or pneumonitis were 
excluded.
Assessments
During treatment, subjects were followed every cycle for 
efficacy and toxicity. After the active treatment phase, 
subjects were followed every 6 weeks and were imaged 
with a Technicium99 bone scintigraphy and computed 
tomography8 scan of the chest, abdomen, and pelvis every 
12 weeks. PSA was measured at each cycle during the treat-
ment phase and then every 6 weeks. Any PSA progression 
or radiographic progression during the first 12 weeks 
required confirmation after week 12 on study. All adverse 
events were recorded from the time the consent form was 
signed through 30 days following cessation of treatment. 
This follow- up schedule continued until disease progres-
sion. Following progression, patients were followed for 
survival by telephone contact every 3 months.
endpoints
The primary endpoint of the study was a confirmed serum 
PSA decrease ≥50% at any time on treatment. Secondary 
endpoints were PSA progression- free survival (PFS), 
objective response, radiographic PFS per RECIST V.1.1, 
time to next treatment and overall survival. Exploratory 
endpoints were the fraction of PD- L1 expressing tumor 
cells and the number of genetic mutations per biopsy, 
including testing for microsatellite instability (MSI) and 
mutations associated with DNA- repair defects.
All baseline tumor biopsies underwent analysis by 
whole exome sequencing (WES) for samples containing 
≥10% tumor or by genotyping using the Knight Diag-
nostic Laboratory’s GeneTrails Solid Tumor Panel of 124 
genes frequently altered in cancer, which assessed single 
nucleotide variations, multinucleotide variations, indels, 
and copy number variations if the sample contained 
<10% tumor.21 Two patients were tested using the 
Personal Genome Diagnostics panel (Baltimore, Mary-
land, USA), which tested 203 genes for the same features 
as the GeneTrails test.22 All responders underwent WES 
regardless of tumor content. MSI was assessed by PCR of 
BAT-25, BAT-26, NR-21, NR-24, MONO-27 for all patients, 
with orthogonal MSI analysis of almost 3000 different 
markers using microsatellite instability detection by next 
generation sequencing (mSINGS).23 DNA- repair genes 
examined included well- described markers (BRCA2, 
ATM, FANCA, CHEK2, BRCA1, PALB2, HDAC2, RAD51, 
MLH3, ERCC3, MRE11, NBN) as well as markers that 
could potentially have clinical relevance (BARD1, BRIP1, 
CDK12, RAD51B, RAD51C, RAD51D, RAD54L).
WES reads were aligned against the GrCH37d5 genome 
using the Sanger cppmap workflow (https:// github. com/ 
cancerit/ dockstore- cgpmap) with realignment around 
indels and base recalibration performed using the Open 
Genomics GATK cocleaning workflow (https:// github. 
com/ OpenGenomics/ gatk- cocleaning- tool). The Mbp of 
genome covered by WES was determined using bedtools 
genomecov (V.2.26.0), where any base pair covered 
by at least six aligned reads was considered covered,24 
human leukocyte antigen (HLA) typing was performed 
from WES reads using Optitype (V.1.3.1).25 Somatic vari-
ants were called using a collection of callers via the mc3 
workflow26 (https:// github. com/ opengenomics/ mc3), 
retaining all variants produced by Pindel and all variants 
reported by two or more tools that were not overlapped 
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Table 1 Baseline characteristics
Characteristics Number of patients
Patients enrolled 28
Age, years   
  Median 72
  Range 61–90
Race   
  Asian 1
  Caucasian 27
ECOG PS   
  0 11
  1 17
Treatment of the primary
  Radical prostatectomy 11
  Radiation therapy 8
  None 9
Gleason score at diagnosis (n=24)   
  ≤6 1
  7 9
  ≥8 14
Clinical stage at diagnosis (n=17)   
  T1c 7
  T2b 6
  T2c 3
  T3 1
  M0 5
  M1 12
Pathological stage (n=11)   
  T2 6
  T3 5
  N0 6
  N1 5
Sites of metastatic disease   
  Bone only 13
  LNs only 3
  Bone and LN 9
  Lung 1
  Liver 2
  Number with measurable disease 12
  Lesion that could be biopsied 17
PSA, ng/mL   
  Median 26.61
  Range 3.03–2502.75
  Hemoglobin, g/dL   
  Median 12.9
  Range 8.9–15.1
Alkaline phosphatase, U/L, at enrollment
Continued
Characteristics Number of patients
  Median 71
  Range 35–568
Lactate dehydrogenase, U/L, at enrollment
  Median 213
  Range 144–1432
C reactive protein, mg/L, at enrollment (n=27)
  Median 5.1
  Range <2.9–130
Prior therapies   
  Docetaxel for castration- sensitive 
disease
4
  Abiraterone 10
  Enzalutamide 28
  Radium-223 1
  Sipuleucel- T 5
Number of weeks on enzalutamide prior to study
  Median 51.9
  Range 22.9–230.3
ECOG PS, Eastern cooperative oncology group performance 
status; LN, lymph node; PSA, prostate- specific antigen.
Table 1 Continued
by a Pindel variant. Germline variants were called using 
GATK HaplotypeCaller (V.3.7-0- gcfedb6),27 using Vari-
antFiltration with cluster size 3 and cluster window size 
15 to flag and subsequently eliminate variants with total 
coverage of <10.0 reads, quality by read depth of <2.0, 
and Phred quality of <100.0. HapCUT2 was used for 
patient- specific haplotype phasing28 by first combining 
germline and consensus somatic variants into a single 
variable call format (VCF) using neoepiscope’s merge 
functionality, then running HapCUT2’s extractHAIRS, 
allowing for extraction of reads spanning indels, to 
produce the fragment file used with HapCUT2 to predict 
haplotypes. Neoepitopes for each patient were predicted 
using neoepiscope29 (V.0.3.5), enumerating peptides of 
8–11 in length from phased variants on protein coding, 
nonsense- mediated decay, polymorphic pseudogene, 
T cell receptor variable, and immunoglobulin variable 
transcripts. Binding predictions for neoepitopes were 
performed using netMHCpan (V.4.0). Only peptides 
which bound at least one of a patient’s major histocom-
patibility complex (MHC) Class I alleles predicted by 
Optitype were retained.
Formalin- fixed, paraffin- embedded tumor samples 
were sent to a commercial vendor (Qualtek) for PD- L1 
quantification by immunohistochemistry (clone 22C3). 
Additional methods details are described elsewhere.30
Levels of serum cytokines and chemokines pretreat-
ment and post- treatment were measured in triplicate 
using a Cytokine/Chemokine/Growth Factor 45- Plex 
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Figure 1 Radiographic and PSA changes. (A) Radiographs of the responders who had measurable disease. (B) Spider plot 
for changes in radiographic response for participants with measurable disease. (C) Changes in PSA for all participants. PSA, 
prostate- specific antigen; RECIST PD, RECIST progressive disease; RECIST SD, RECIST stable disease.
Human ProcartaPlex Panel 1 kit (ThermoFisher Scien-
tific, Waltham, Massachusetts, USA) and Luminex 
200 (Austin, Texas, USA). Among the list of 45 unique 
analytes, the following 11 analytes were detectable: MIP-1 
alpha/CCL3, LIF, IP-10/CXCL10, IL-7; Eotaxin/CCL11, 
PIGF-1, IL- 1RA, RANTES/CCL5, HGF, BDNF, and 
PDGF- BB.
Whole blood immune profiling assays were conducted 
as previously described.31 Briefly, heparinized whole blood 
was stained with a cocktail of antibodies to identify T cell 
subsets as well as monocytic myeloid- derived suppressor 
cells (MDSCs). Stained cells were then incubated with 
BD fluorescence- activated cell sorting (FACS) lysing solu-
tion (BD Biosciences, Franklin Lakes, New Jersey, USA) 
followed by washes. For intracellular antigens (eg, Ki-67, 
granzyme B, and perforin), cells were permeabilized with 
the Permeabilizing Solution 2 (BD Biosciences) followed 
by incubation with staining antibodies. Samples were then 
acquired with a BD LSRFortessa (BD Biosciences). Data 
were analyzed with FlowJo V.9 (FlowJo, LLC, Ashland, 
Oregon, USA). The levels of activation (CD38, HLA- 
DR), proliferation (Ki-67), and functional (granzyme 
B, perforin) markers were assessed on effector memory 
(CD45RA−CCR7−) CD4 and CD8 T cell subsets. Mono-
cytic MDSCs were defined as lineage (CD3, CD7, CD19, 
and CD20) negative, CD15−CD11b+CD33+CD14+HLA- 
DRlow and the frequency of MDSCs within the lymphocyte 
plus monocyte gate was used to assess their relationship 
to treatment effect.
Power analysis and statistical methods
Patients with PSA progression on enzalutamide are unlikely 
to have a spontaneous PSA response without a change in 
therapy. We deemed that a 25% response rate (defined as 
a PSA decrease ≥50%) to pembrolizumab observed here 
would be worthy of further study. Using a null hypothesis of 
5% and alternate hypothesis of 25%, 25 evaluable patients 
were needed with 90% power and a one- sided alpha of 
0.05. To account for potential drop- out, we enrolled 28 
subjects. Descriptive statistical analyses were conducted for 
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1 – + 5/5 ↑ ATM R1618Q LN 4428 (3.41) 113
2 – – 0/5 ↓ Absent Liver 352 (0.32) 24
3 – – 0/5 ↓ Absent Liver 210 (0.15) 7
Non- responders
1 NTD – 1/5 ↓ Absent Bone –
2 NTD – 0/5 ↓ Absent Bone –
3 NTD – 0/5 ↓ Absent LN 204 (0.43) 12
4 – + 0/5 ↓ Absent Bone 154 (0.37) 2
5 – – 0/5 ↓ Absent LN –
6 – – 0/5 ↓ Absent LN 201 (0.24) 6
7 – – 0/5 ↓ FANCC D195V Bone –
8 – – 0/5 ↓ Absent Bone –
9 – – 0/5 ↓ CHK2 I157T Soft tissue 475 (0.50) 20
10 – – 0/5 ↓ Absent Bone –
11 – – 0/5 ↓ FANCA G1092Rfs*1116 Bone –
12 – – 0/5 ↓ Absent LN 235 (0.32) 124
13 – + 0/5 ↓ Absent LN 167 (0.18) 8
*Subjects who had WES.
–, absent; +, present; LN, lymph node; MSI, microsatellite instability; NTD, no tumor detected; PD- L1, programmed death- ligand 1; TIL, 
tumor- infiltrating lymphocyte; WES, whole exome sequencing.
all variables of interest. Kaplan- Meier method was used to 
estimate the distribution of overall survival and PFS. Exact 
binomial test was used to determine whether the response 
rate was significantly >5%. Statistical analysis for clinical 
endpoints were conducted in R V.3.4.3.
The following statistical analyses were done using Prism 
V.7 (GraphPad Software; La Jolla, California, USA). The 
effect of the treatment on serum CXCL10 levels and CD38, 
HLA- DR, and Ki-67 expression on CD4 and CD8 effector 
memory T cells were first determined by a repeated 
measures one- way analysis of variance test. Once statis-
tical differences in means were confirmed, the difference 
between two timepoints was assessed by the paired Student’s 
t- test. A p value of <0.05 was considered significant. The 
difference between non- responders and responders in 
baseline perforin or granzyme B expression in CD8 effector 
memory T cells as well as a baseline frequency of MDSCs 
were evaluated using an unpaired Student’s t- test. Survival 
curves are depicted using a Kaplan- Meier method and the 
relationship between the baseline perforin, granzyme B, or 
MDSCs and PFS was determined by log- rank test.
results
Patients
Twenty- eight men were enrolled at the Knight Cancer 
Institute, Oregon Health & Science University, from 
April 2015 to August 2016. The median age was 72 years 
(range 52–90, table 1). Seventeen patients underwent 
a biopsy of a metastatic tumor prior to treatment. The 
median number of treatments for mCRPC prior to study 
entry was 2. Median time on enzalutamide prior to study 
entry was 52 weeks (range 23–230). Twenty- three (82%) 
patients had a PSA response on enzalutamide prior to 
progression. Five patients received sipuleucel- T as stan-
dard therapy prior to study entry.
treatment
The median number of pembrolizumab doses was 
4 (range 2–12), and patients with best response of 
stable disease and no evidence of radiographic or clin-
ical progression were treated with a second course of 
pembrolizumab for progressive disease. None of the non- 
responders converted to responders with a second course 
of pembrolizumab.
Anti-tumor activity
Five (18%, 95% CI: 0.06 to 0.37) of 28 men met the primary 
endpoint of PSA decrease of 50% or greater from start of 
treatment. The response rate is significantly greater than 
5%, our planned null hypothesis (p=0.01171, exact bino-
mial test). Of the five PSA responders, three had measur-
able soft tissue disease. All three of these patients had a 
partial radiographic response (figure 1); the other two 
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Figure 2 Distribution of mutational burden in responder’s 
versus non- responders. Boxplot showing the distributions 
of mutational burden (left) and neoepitope count (right) for 
responders versus non- responders. The center line in each 
box represents the median, with bottom and top boundaries 
of the box representing the first and third quartiles, 
respectively. Lines extending down and up from the box 
represent the minimum and maximum values, respectively. 
Non- responders are shown in light blue, and responders 
are shown in dark blue. There was no statistically significant 
difference between responders and non- responders in 
terms of mutational burden (median 6.5 vs 4.9 variants per 
megabase pair covered, p=0.42) or predicted neoepitope 
burden (679 vs 405.5 neoepitopes, p=0.42).
responders were not assessable via radiographic metrics 
such as RECIST because they had bone- only disease. 
One of the responders subsequently died of pancreatic 
cancer with an undetectable PSA, 22.5 months following 
enrollment. Another responder had PSA progression 36 
months after cycle 1, but died of a cerebrovascular event 
42.4 months. One patient developed PSA progression 
after 10 months, and subsequently received a second and 
third course of pembrolizumab without a PSA response. 
However, that patient did not require a new antineo-
plastic treatment for 26.8 months after enrollment. The 
remaining two responders continue to have a sustained 
PSA response after 39.3, and 37.7 months without 
any additional therapy. Of note, one of them has not 
continued enzalutamide therapy, but the other one has.
Twelve (43%) of the patients had RECIST measur-
able disease. Three patients achieved a partial response 
(25%), four had disease progression and five had stable 
disease. One of the three partial responders has not 
relapsed after 39.3 months. Another partial responder 
progressed by imaging after 36.4 months, while the third 
partial responder did not show radiographic progres-
sion prior to starting a new cancer treatment. However, 
RECIST is an incomplete metric of response in this 
cohort, as there were many patients with stable disease 
by RECIST criteria that exhibited clear PSA progression 
or durable PSA response (figure 1). Among patients with 
radiographically measurable disease, we note additional 
small discrepancies between overall RECIST scoring 
and biopsied lesion- specific measurements (figure 1). 
For instance, at least two patients with stable disease 
by RECIST criteria exhibited clear growth of biopsied 
lesions. These same patients also exhibited PSA progres-
sion, with 16%–20% increase over baseline by their last 
cycle of pembrolizumab therapy.
For the entire cohort, the median follow- up was 37 
months, and the median PSA PFS time was 3.8 months 
(95% CI: 2.8 to 9.9 months). Median time to subsequent 
treatment was 7.2 months (95% CI: 5.1 to 11.1 months). 
Median overall survival was 22.2 months (95% CI: 14.7 to 
28.4 months). For the five responders, median follow- up 
was 38 months and the duration of response to date is 
21.9 to NR months. Two are still in partial response after 
39.3 and 37.8 months of follow- up. Median PSA PFS time 
was 36.1 months (95% 9.9 to NR), and time to subsequent 
treatment was not achieved. The median overall survival 
for the responders was 41.7 months (95% CI: 22.2 to 
NR). For the 23 non- responders, median follow- up time 
was 36.5 months; median PSA PFS time was 3.1 months 
(95% CI: 2.8 to 4.4 months); median time to subsequent 
treatment was 5.2 months (95% CI: 3.8 to 8.5 months); 
and overall survival was 18.6 months (95% CI: 13.4 to 26.4 
months). Twenty- two of 28 men have died, and all but 
three of those deaths were attributable to prostate cancer. 
PSA histories and response trajectories are distinct 
between responders and non- responders (figure 1). 
None of the five patients who had received sipuleucel- T 
responded to pembrolizumab
exploratory endpoints
Seventeen (61%) of 28 participants had a baseline biopsy 
of a metastatic lesion. Three of the five responders had 
a baseline biopsy, and there were 14 biopsies among the 
non- responders, 13 of which had identifiable tumor. One 
of the responders exhibited substantial MSI (assessed 
by both PCR and mSINGS) with over 4000 mutations 
in his tumor (table 2). He also had mutations in several 
DNA- repair genes, with at least one known heterozygous 
deleterious (cancer- predisposing) variant in Ataxia- 
Telangiesctasia Mutated (ATM). The other two responders 
had no markers of MSI and 352 and 210 total mutations 
in their tumors, respectively. One non- responder had 
a single marker of MSI by PCR but was not deemed 
MSI high by mSINGS,23 and three non- responders had 
heterozygous mutations in DNA- repair pathways (two 
of which are thought to be cancer- associated). All 17 
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Figure 3 Pembrolizumab plus enzalutamide treatment induced systemic immune responses. (A) Serum CXCL10 levels 
pretreatment (C1D1; Cycle 1 Day 1) and post- treatment (C2D1, Cycle 2 Day1; C3D1, Cycle 3 Day 1) are shown (n=22). (B) The 
percent expression of CD38, HLA- DR, or Ki-67 in EM CD4 or CD8 T cells is shown (n=18). EM, effector memory; NS, not 
significant.
baseline biopsies were sent for PD- L1 staining, and none 
were found to have PD- L1 present on cancer cells. Gene 
expression profiling of total tumor confirmed PD- L1 
expression was not different between responders and 
non- responders (data not shown). In one responder 
and two non- responders, PD- L1 was detected on tumor- 
infiltrating lymphocytes (TILs, table 2).
To compare mutational burden and possible neoepi-
topes among patients with WES data, normalized values 
(ie, the number of somatic variants/genomic coverage) 
were compared between responders (n=3) and non- 
responders (n=6), with no statistically significant differ-
ence observed between groups (median 6.5 vs 4.9, 
respectively, p=0.42, online supplementary figure 1). 
Comparison of predicted neoepitope burden between 
groups, predicted from WES data, demonstrated a trend 
toward higher numbers of predicted neoepitopes among 
responders (679 vs 405.5, p=0.42, figure 2).
Markers of pharmacological activity and immuno-
logical activity to pembrolizumab/enzalutamide were 
measured by examining changes in serum cytokines and 
chemokines as well as circulating leukocytes pretreatment 
and post- treatment. We detected elevated CXCL10 levels 
following treatment (figure 3A), suggesting that this 
approach effectively induced a proinflammatory (type-1; 
Th1) immune response.32 There was no significant differ-
ence in CXCL10 levels between non- responders and 
responders at baseline or fold change over the course 
of treatment suggesting that CXCL10 is a pharmacody-
namic marker rather than an immune correlate of clin-
ical responsiveness. Next, we assessed the activation and 
proliferation of effector memory (CCR7−CD45RA−) 
CD4 and CD8 T cells by flow cytometry. We observed 
increased activation of effector memory CD4 and CD8 
T cells as assessed by changes in CD38 and HLA- DR at 
the end of cycle 1 (C2D1; Cycle 2 Day 1). Moreover, these 
T cell subsets maintained a similar level of activation at 
the C3D1 timepoint (figure 3B, top two rows). We also 
detected increased proliferation of effector memory CD4 
and CD8 T cells on treatment (figure 3B, bottom row). 
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Figure 4 The functional status of EM CD8 T cells as 
a potential immune correlate with clinical response and 
outcome. (A) The percent expression of GzmB or perforin in 
EM CD8 T cells is compared between non- responders (NR; 
n=14) and responders (R; n=4). (B) Kaplan- Meier curves 
demonstrating that patients with higher median percentage 
of perforin, but not GzmB, EM CD8 T cells at baseline had 
prolonged PFS. (C) The frequency of MDSCs at baseline did 
not correlate with clinical response or outcome. EM, effector 
memory; GzmB, granzyme B; MDSCs, myeloid- derived 
suppressor cells; PFS, progression- free survival.
Interestingly, proliferation of effector memory CD4 T 
cells was sustained even at the C3D1 time point, whereas 
effector memory CD8 T cell proliferation returned to the 
pretreatment levels by this time. The extent of effector 
memory T cell activation and proliferation was similar 
between the non- responder and responder cohorts (data 
not shown). We also examined MIP- 1alpha, RANTES, 
and Eotaxin expression, but did not find any significant 
changes in these cytokines/chemokines following treat-
ment (online supplementary figure 1). The percent of B 
cells and natural killer cells also did not change (online 
supplementary figure 2).
We asked whether there were any correlations between 
pre- existing immune subsets and clinical responses. 
Interestingly, we found that the frequency of granzyme 
B+effector memory CD8 T cells was significantly higher in 
responders than non- responders (figure 4A, left). Simi-
larly, we observed a trend of increased perforin+effector 
memory CD8 T cells in responders (figure 4A, right), 
suggesting that responding patients may harbor a pre- 
existing pool of cytotoxic tumor- reactive T cells. Further 
analysis revealed that when patients were grouped based 
on the frequency of granzyme B or perforin- expressing 
effector memory CD8 T cells, patients with increased 
perforin expression had improved PFS (figure 4B). In 
contrast, there was no correlation between the frequency 
of MDSCs with clinical response or outcome (figure 4C). 
Taken together, these data suggest that the clinical benefit 
of pembrolizumab plus enzalutamide may require the 
presence of pre- existing tumor- reactive CD8 T cells.
safety
There were seven patients with immune- related adverse 
events (irAE, see table 3). Two patients had colitis, three 
had hypothyroidism, one had hyperthyroidism, and 
two had myositis. The colitis resolved for both patients 
after aggressive treatment with high- dose steroids plus 
mesalamine or infliximab. Patients with hypothyroidism 
continue on thyroid replacement, and the patient with 
hyperthyroid received methimazole with resolution. The 
patients with myositis received high- dose steroids with a 
taper lasting 3 months. Four patients discontinued treat-
ment due to irAEs after 2–4 doses of pembrolizumab. 
No patient developed an irAE on the second course of 
pembrolizumab. Most adverse events were as expected 
with enzalutamide and prostate cancer, except that two of 
the responders were diagnosed with a second malignancy 
while on therapy. One patient developed metastatic 
pancreatic cancer. A second patient, who was a non- 
smoker and had received radiation to the prostate bed 
12 years prior to pembrolizumab treatment, developed 
superficial bladder cancer. Neither event was felt to be 
related to pembrolizumab. One responder had immune- 
related colitis and myositis.
disCussion
This study is the first to demonstrate that PD-1 checkpoint 
inhibition in mCRPC can produce profound and durable 
responses as assessed by both PSA and radiographic 
criteria in a subset of patients. This study also introduces 
a novel paradigm for assessing biopsied lesion- specific 
responses when interpreting tumor- sequencing data.
Recently, PD-1 inhibitors were approved for any tumor 
type that exhibits high MSI.20 In prostate cancer, estimates 
of MSI vary, but may be as high as 12%.33 One responder 
in this study was found to have MSI, but it is clear that 
this is not the principal driver of response as two other 
responders with baseline tissue did not exhibit MSI. Only 
one metastatic lesion per patient was biopsied for this 
study, and these lesions responded to pembrolizumab 
despite the absence of MSI. While there has been some 
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Table 3 Adverse events
Toxicity Number of patients
OutcomesGrade 2 3 4 5
Immune
  Colitis 2 High- dose steroids for both; argon laser for one and 
infliximab for one; mesalamine for the other now resolved.
  Myositis 2 High- dose steroids and resolved.
  Hyperthyroidism 1 High- dose steroids improve
  Hypothyroidism 3 Started on thyroid replacement
All >grade 2   
  Myelitis 1   
  Femoral fracture 1   
  Spinal fracture 2   
  Hypertension 3   
  Anemia 1   
  Fatigue 1   
  Enterocolitis infectious 1   
  Hyponatremia 1   
  Glaucoma 1   
  Urinary tract obstruction 1   
  Urinary tract infection 1   
  Humeral Fracture 1   
  Neoplasm bladder 1   
  Neoplasm pancreas 1   
discussion about the best markers to detect MSI in pros-
tate cancer tumors,34 current MSI measurements do not 
appear to be a universal predictor of PD-1 response in the 
enzalutamide- refractory prostate cancer setting. Prostate 
cancers with CDK12 loss may have more susceptibility to 
checkpoint inhibition,35 but we did not find this mutation 
in the three responders who had baseline biopsies.
In contrast to recent publications,13 18 this study showed 
that mCRPC does not routinely express PD- L1, even after 
the development of resistance to enzalutamide. Notably, 
our initial publication described PD- L1 expression on 
tumor cells, but on further study, only TILs showed 
expression. This study therefore demonstrates that PD- L1 
expression in tumor biopsies is not necessary for anti-
tumor activity of pembrolizumab, consistent with several 
prior studies in other tumor types.36
Another study examined the effect of AR- V7 positivity 
on the effectiveness of checkpoint inhibition using ipilu-
mumab and nivolumab.37 The investigators hypothesized 
that AR- V7 positivity correlated with DNA- repair defects 
and might make them more sensitive to checkpoint 
inhibitors. They treated 15 men with mCRPC with both 
ipilimumab and pembrolizumab and found that of the six 
patients who had DNA- repair defects, PSA PFS was longer 
than for the nine who did not. In our group of patients, 
4 of the 16 evaluable patients had a putative DNA- repair 
defect,38 and only one responded to treatment, likely 
because he also had MSI. An additional study explored 
nivolumab and ipilimumab in non- molecularly selected 
patients. They found a 21% PSA response rate and 26% 
radiographic response rate in men who had not received 
chemotherapy for mCRPC.38
This study has several limitations. Many clinically 
approved regimens of PD-1 inhibitors allow for indefinite 
use, but only four cycles of pembrolizumab were used in 
this study design. While the vast majority of subjects had 
already demonstrated a clear disease trajectory after four 
cycles of therapy, there were several patients with stable 
disease whose PSA began rising after cessation of therapy. It 
is possible that we could have seen more prolonged stable 
disease with continued use of PD-1 inhibitors in some 
patients, but it is also notable that our responders enjoyed 
continued remissions long after completion of four doses 
of pembrolizumab. Retreatment of non- responders with 
initial stable disease did not yield responses. Our study is 
small, and there is a company sponsored trial (KEYNOTE-
199, cohorts 4 and 5) exploring response rates to pembroli-
zumab following progression on enzalutamide in 120 
additional patients (NCT02787005).
Since our initial study design, multiple additional trials 
for mCRPC have been launched to explore combina-
tion therapy of checkpoint inhibitors with enzalutamide 
and other partners such as PARP inhibitors, radium-
223, chemotherapy and other immunotherapies.15 39 40 
10 Graff JN, et al. J Immunother Cancer 2020;8:e000642. doi:10.1136/jitc-2020-000642
Open access 
Preliminary results with PARP inhibitors in combination 
with a PD- L1 inhibitor show that a subset of patients 
respond, even if their tumors do not harbor DNA- repair 
defects.40 These results provide the rationale for further 
testing of that combination and correlative studies to 
reveal determinants of response. The impact of single 
agent enzalutamide on the immune system is being exam-
ined in an additional study (NCT02484404).
ConClusion
PD-1 inhibition has activity in mCRPC—including 
in patients whose tumors appear to lack MSI, DNA- 
repair defects, or PD- L1 expression. Further studies are 
warranted to more accurately reveal the activity of PD-1 
inhibition in men with mCRPC and to clarify markers of 
response. Observed responses were deep, durable and 
achieved after only four doses of pembrolizumab.
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